SAN FRANCISCO – Researchers at the University of California, San Francisco have identified a protein that accelerates age-related cognitive decline and shown that reducing it can restore memory and brain function in older mice. The findings, published this week in Nature Aging, are raising hopes for new treatments to slow or even reverse aspects of brain aging in humans.
The protein, known as FTL1, or ferritin light chain 1, was found in significantly higher amounts in the hippocampus of aged mice compared to young ones. The hippocampus is a brain region central to learning and memory, and it is among the first areas affected in age-related cognitive decline and Alzheimer’s disease. When scientists reduced FTL1 levels in older mice, their memory performance and brain structure improved to levels closer to those of much younger animals.
“This is the first time we have identified FTL1 as a molecular driver of hippocampal aging,” said Dr. Saul Villeda, senior author of the study and a researcher at UCSF’s Bakar Aging Research Institute. “By targeting this protein, we were able to restore both brain connectivity and memory. It is truly a reversal of impairments.” (UCSF News)
Testing the Limits of Brain Plasticity
To reach these conclusions, the researchers conducted genetic and biochemical analyses of hippocampal tissue from young and aged mice. FTL1 stood out as one of the most elevated proteins in older brains. In follow-up experiments, the team artificially increased FTL1 in young mice. Those animals soon developed memory problems and structural brain changes that resembled accelerated aging.
Conversely, when scientists reduced FTL1 in old mice, the results were striking. Neurons regained youthful branching patterns, synaptic proteins increased, and memory improved on a range of behavioral tests, including navigating mazes and recognizing new objects.
“These results suggest that even an aged brain retains a remarkable capacity for recovery if the right molecular switches can be targeted,” said Villeda.
The Science Behind FTL1
FTL1 is a component of ferritin, the protein complex that stores and regulates iron in cells. While iron is essential for energy production, excessive or mismanaged iron can damage cells by fueling oxidative stress. The study found that excess FTL1 in aging neurons disrupted iron balance and impaired cellular metabolism.
Laboratory-grown neurons engineered to overproduce FTL1 developed fewer dendrites, the tree-like extensions needed for synaptic connections. By contrast, neurons in which FTL1 was suppressed regained complexity and resilience.
“This adds to a growing body of evidence that iron metabolism and mitochondrial health are central to the aging process,” said Dr. Li Gan, director of the UCSF Weill Institute for Neurosciences, who was not involved in the study. “The fact that a single protein can have such dramatic effects is both exciting and surprising.”
Implications for Human Health
Although the research was conducted in mice, experts say the findings could have significant implications for humans. Age-related cognitive decline affects tens of millions worldwide, and Alzheimer’s disease remains the most common form of dementia with no cure.
The identification of FTL1 as a potential therapeutic target suggests new strategies for preventing or delaying memory loss. Unlike drugs that treat symptoms, interventions aimed at proteins like FTL1 could address the root causes of neuronal decline.
Still, scientists caution that translating the findings to people will take time. The human brain is vastly more complex than that of mice, and treatments that work in laboratory animals often fail in clinical trials. “We need to be cautious but optimistic,” Villeda said. “This is an important first step, but much more work is needed before we can think about therapies.”
Looking Ahead
The UCSF team is now exploring whether reducing FTL1 in other brain regions produces similar benefits and whether the protein is elevated in human patients with cognitive decline. Pharmaceutical companies may also investigate compounds that can selectively block or lower FTL1 activity.
According to the researchers, the broader lesson is that brain aging may be more reversible than once thought. By targeting specific molecular pathways, it may be possible not just to slow decline but to restore lost function.
“We are beginning to understand that aging is not a one-way street,” Villeda said. “If we can intervene at the right targets, we may be able to help people maintain memory and independence much longer than we thought possible.”